How Much Does Pfizer Inc Spend on Lobbying?

Pfizer Inc's disclosed federal lobbying spend of $54.4M places it among the top-tier spenders tracked here — organizations that put real, recurring dollars behind their federal advocacy. Spending at this level usually involves a dedicated in-house team, multiple outside firms, and steady quarterly filings rather than one-off campaigns tied to a single bill.

Pfizer Inc's disclosed lobbying covers 8 general issue areas — a moderate footprint. Filers in this range tend to engage on a coherent cluster of related topics rather than spreading effort across the federal agenda.

The Senate Lobbying Disclosure Act requires anyone who contacts covered federal officials on behalf of a paying client — and crosses time and dollar thresholds — to register and file quarterly. Filings are publicly available through the Senate Office of Public Records, which is the original source for every dollar figure on this page. The same filings feed downstream research at OpenSecrets, where you can cross-reference individual lobbyists, bills tracked, and related campaign contributions.

14 of 36 lobbyists reported by Pfizer Inc (39%) disclose prior federal government service. That share is common at established government affairs operations that explicitly hire from agency and committee staff.

Among the named bench, lobbyists with disclosed prior federal service include Andrew B. Garcia (Former Senior Counsel, Senate Finance Committee); Stanley L. Garnett (Former Professional Staff Member, Senate Appropriations Committee); Nancy P. Carter (Former Staff Director, Senate Banking Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Pfizer Inc ranks #0 of 33 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $15.6M. Pfizer Inc's $54.4M sits 249% above the sector average.

Pfizer Inc's LobbySpend Influence Score of 70/100 (grade B) reflects significant federal lobbying reach. The score blends disclosed total spend, issue breadth, and revolving-door connections — lobbyists with prior federal government service. A B-grade typically means the organization is well above average on at least two of those three signals, with sustained activity over multiple years rather than a one-off spike.

Across the 5-year window from 2020 to 2024, Pfizer Inc's annual disclosed lobbying spend has declined modestly — from $10.9M in 2020 to $10.1M in 2024, a change of -8%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.

Every dollar on this page comes from quarterly filings submitted under the Lobbying Disclosure Act and published by the Senate Office of Public Records. We pull those filings via the lda.senate.gov public API, deduplicate amendments, and aggregate by registrant or client across the years shown. The "amount" for each filing is the larger of reported income (for lobbying firms) or reported expenses (for in-house programs), which is the standard convention used by both the Senate's own dashboards and outside researchers including OpenSecrets.

The LobbySpend Influence Score is a composite indicator: 40% disclosed total spend, 30% number of distinct general issue areas lobbied on, and 30% share of named lobbyists with prior federal government service. The score is descriptive — it summarizes what was disclosed — and should not be read as a measure of effectiveness, ethics, or political outcomes. Read the full methodology for the exact formulas, caveats, and known limitations of LDA disclosures.